Key Statistical Concepts in Clinical Trials for Pharma (Record no. 101111)

000 -LEADER
fixed length control field 02269nam a22004335i 4500
001 - CONTROL NUMBER
control field 978-1-4614-1662-3
003 - CONTROL NUMBER IDENTIFIER
control field DE-He213
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140220083243.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 111012s2012 xxu| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781461416623
-- 978-1-4614-1662-3
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1007/978-1-4614-1662-3
Source of number or code doi
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number R-RZ
072 #7 - SUBJECT CATEGORY CODE
Subject category code MBGR
Source bicssc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED000000
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 610
Edition number 23
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Turner, J. Rick.
Relator term author.
245 10 - TITLE STATEMENT
Title Key Statistical Concepts in Clinical Trials for Pharma
Medium [electronic resource] /
Statement of responsibility, etc by J. Rick Turner.
264 #1 -
-- New York, NY :
-- Springer New York,
-- 2012.
300 ## - PHYSICAL DESCRIPTION
Extent IX, 61p. 1 illus.
Other physical details online resource.
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
347 ## -
-- text file
-- PDF
-- rda
490 1# - SERIES STATEMENT
Series statement SpringerBriefs in Pharmaceutical Science & Drug Development,
International Standard Serial Number 1864-8118
520 ## - SUMMARY, ETC.
Summary, etc This Brief discusses key statistical concepts that facilitate the inferential analysis of data collected from a group of individuals participating in a pharmaceutical clinical trial, the estimation of their clinical significance in the general population of individuals likely to be prescribed the drug if approved, and the related decision-making that occurs at both the public health level (by regulatory agencies when deciding whether or not to approve a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical technology.
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biomedicine general.
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical Sciences/Technology.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9781461416616
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title SpringerBriefs in Pharmaceutical Science & Drug Development,
-- 1864-8118
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-1-4614-1662-3
912 ## -
-- ZDB-2-SBL

No items available.

2017 | The Technical University of Kenya Library | +254(020) 2219929, 3341639, 3343672 | library@tukenya.ac.ke | Haile Selassie Avenue